Imunovir™ (inosine pranobex) is an immunomodulator of the potentiator type which has demonstrated an enhancing effect on the function and number of various cells of the immune system, particularly T lymphocytes, which are responsible for defending the body against viral and fungal infections . Imunovir's™ ability to enhance the functions of various cells within the immune system seems likely to be accountable for its clinical efficacy. It is our belief that therapy with an agent capable of enhancing certain aspects of the immune response system is a logical approach to the treatment of disorders associated with an underlying cellular immune defect. These include viral diseases and immune deficiency states.

Imunovir™ is also known in different parts of the world as Isoprinosine^®, Viruxan^®, Prinosine^® and Virimun^®. It is approved for a variety of viral infections resulting from depression of the immune system. A partial list includes Aolpecia areata, CMV, EBV, Hepatitis acute and non-chirrotic chronic active B, Influenza, Measles Mumps, Viral conjunctivitis and subacute sclerosing panencephalitis (SSPE). A study published in the 11th volume of the Journal of Chronic Fatigue Syndrome™, entitled "Clinical Improvement in Chronic Fatigue Syndrome Is Associated With Enhanced Natural Killer Cell-Mediated Cytotoxicity: The Results of a Pilot Study with Isoprinosine^®". However, its use in this indication is still considered investigational. Imunovir™ is approved for the treatment of SSPE in Canada.

Imunovir™ is available in 500 mg tablets and is supplied in bottles of 100 tablets. It is a prescription-only medication in Canada.

Imunovir™ is the trademark of Newport Pharmaceuticals Limited.